Erdafitinib demonstrates improved responses in FGFR-altered advanced urinary tract cancers
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib improved responses and overall survival compared to standard chemotherapy for patients with metastatic urothelial cancers with FGFR ...
Oct 23, 2023
0
0